We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.00 | 2.80 | 3.20 | 3.00 | 3.00 | 3.00 | 120,404 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.33 | 142.99M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/7/2018 06:18 | A good solid set of results, hopefully trial results are good in Q3 | richsawko | |
04/7/2018 18:00 | Last year on July 18th we had a Trading update. This one this year if they release one should be a cracker! impo/dyor | jimmyloser | |
04/7/2018 15:15 | Ah, filling a gap. thanks for response. | stefanj26 | |
04/7/2018 14:52 | I cannot explain it but that is what the chart indicates. Maybe an overhang filling a sale holding the price back + although I have given up on predicting this market | richsawko | |
04/7/2018 14:46 | Forgive my ignorance, why would a big sell cause a rise in price rather than a fall? | stefanj26 | |
04/7/2018 14:22 | The last time this happened in mid June we had a big jump in price - hoping for the same again! | richsawko | |
04/7/2018 14:20 | Massive sell trades today at 27p? Anyone know of a reason | richsawko | |
29/6/2018 15:31 | Tipped in today’s IC, but reveals nothing all of us here didn’t already know. Pleasing all the same. | dozey3 | |
25/6/2018 07:54 | Some momentum building! | audigger | |
25/6/2018 06:56 | Allergy Therapeutics PLC 25 June 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 25 June 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the publication of positive data in the journal Immunotherapy, demonstrating long-lasting efficacy of Pollinex Quattro Grass in patients with grass pollen allergy. Zielen et al., Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy. doi; 10.2217/imt-2018-000 The observational study, led by Professor Stefan Zielen of the Goethe University, Germany, focused on the long-term efficacy of Pollinex Quattro Grass. Each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy. The study concluded that patients treated with Pollinex Quattro Grass vaccine exhibited significant and long-lasting symptom improvements 3-6 years after cessation of treatment. Professor Stefan Zielen, author of the paper commented; "We are delighted with the publication of our observational study that demonstrates the long-term effects of Pollinex Quattro Grass immunotherapy. Our paper highlights the benefits that this allergen-specific immunotherapy can offer allergy sufferers, in terms of patient convenience, as well as the potential for positive and long-lasting effects." Manuel Llobet, CEO at Allergy Therapeutics, said: "This paper validates earlier studies indicating Pollinex Quattro is disease modifying for the many patients affected by grass allergy. Together with the recently announced positive data from our Phase Grass G205 clinical study, we believe that we have a robust data set for our suite of novel allergy product candidates. We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally, including in the significant US market." The data presented supports earlier studies investigating Pollinex Quattro, Zielen et al., 2007(1) and Rabe et al 2017(2) . Sustained efficacy according to European Medicine Agency criteria in 3114 patients was shown in the 2007 Zielen paper(1) , where after 3 years, improvement of symptoms was reported in more than 93% of patients and the consumption of anti-allergic medication decreased in more than 75% of patients | jimmyloser | |
22/6/2018 09:40 | Yes I think you are right AuDigger but I actually solidly expect that to make its assault on 40p not 30p. The setback was due to a lower allergy environment last year (thankfully for us sufferers) it certainly isn't like that this year! The company have in recent months progressed again and in spades. This as they said earlier, appears to be a potentially "TRANSFORMATIONAL" year. These things take time. impo/dyor | jimmyloser | |
21/6/2018 17:42 | Think its about time it launched an attack on 30p again! | audigger | |
19/6/2018 11:26 | Some big trades just gone through - is something brewing? | richsawko | |
07/6/2018 16:34 | Re jimmyloser 6 Jun '18 - 17:44 - 3433 of 3433 I'm invested here and also in Morphosys (MOR) which has an even more exciting product development pipeline IMO. | jemt0703 | |
06/6/2018 16:44 | I should jolly well think so. We faithful will look back at this price and think that it was a mirage. I do not know of any business with a pipeline anywhere near as interesting as we have here. | jimmyloser | |
29/5/2018 06:15 | Underestimate what this team are doing at your peril! impo/dyor...The day will come when this business will be snapped up.....after stage 3, I suspect! Allergy Therapeutics PLC 29 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics", the "Group" or "Company") Positive new clinical data with house-dust mite immunotherapy House-dust mite immunotherapy shown to be well-tolerated and demonstrates highly significant symptom improvement Allergy experts present an overview of adjuvants at satellite symposium during EAACI 2018 29 May 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy(1) . This data will be presented today at the 37(th) Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany. The Group's modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I, as announced in February 2017. In this observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year (p = <0.0001). In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline (p = <0.01). No patients presented with serious adverse events and no patients had to stop treatment due to any adverse event. Allergy Therapeutics also presented a series of poster presentations at EAACI with key highlights including an overview of the early-phase pre-clinical developments for the Group's planned recombinant peanut vaccine(3) and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy(4) . Other events held by the Group at EAACI included a satellite symposium entitled: "Adjuvants through the ages"(2) which provided a summary of how adjuvant technologies have evolved and how Allergy Therapeutics is spearheading the design and testing of state of the art allergen-specific immunotherapies. Manuel Llobet, Chief Executive Officer, commented: "We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company. The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products." | jimmyloser | |
22/5/2018 17:57 | Some good info in this interview. Must admit that I thought they would be in to the phase 3 program earlier than the Q3 2019 recruitment date stated. Huge opportunity though and the barriers to entry for others will be high so a little more patience required. | audigger | |
22/5/2018 17:51 | Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018 | gersemi | |
22/5/2018 12:16 | Afternoon, Short TV interview with both CEO Manuel Llobet and House broker Panmure Gordon's Healthcare Analyst Dr Mike Mitchell www.fmp-tv.co.uk/com | oshy92 | |
21/5/2018 08:42 | Agreed, I trade ranges which means I almost always sell out too soon! Still, it's putting bread on the table and I'm long term on a couple of favourites. Must admit I like the story here, will be watching closely. | rathean | |
21/5/2018 08:30 | I use to regularly buy and sell these but some day soon it will take off so now I just buy the dips. That said I recently sold a number of other shares which I made money on but have absolutely flown since I sold! Such is investing. A profit is a profit! Will get the Ferrari when they hit 100p! | audigger | |
21/5/2018 08:12 | That's me out with a rather pleasant 10% gain. Very positive news though, will be back in when the price is right, gla. | rathean | |
21/5/2018 07:41 | You could upgrade to a Ferrari at this rate! | richsawko | |
21/5/2018 07:28 | Well there's some proof of concept for you! Looks like I timed my top-up well for once. I'm tempted to add more but spare cash is heading for a car purchase! | audigger | |
21/5/2018 07:28 | WOW 2.5M trade! | richsawko |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions